With approximately 75% of the estimated 36 million Alzheimer’s sufferers worldwide yet to receive a reliable diagnosis, the potential impact on the lives of possible sufferers, present and future, could be huge.
Alzheimer’s disease is a neurodegenerative disease most frequently affecting the elderly. The most commonly associated symptom is a progressive loss of memory to the stage in which the patient is completely dependent on caregivers for their daily needs. There is a large amount of research supporting the theory that a group of peptides called beta amyloid (Aβ), which are found naturally in the body, are major contributors to Alzheimer’s disease. Through a process, so far unclear to science, there is a build up of these peptides in the brain that over a period of years cause memory complaints and other symptoms associated with the disease.
Professor Manuel Sarasa, CSO and founder of Spanish research company Araclon Biotech, and his team have been perfecting blood tests “ABtest40″ and “ABtest42″ to measure the very small amounts of these peptides in the blood.
“The study has shown that our tests for Aβ in blood find a high level of association between the peptide levels and the disease when comparing healthy people and people with mild cognitive impairment” ((MCI) the earliest noticeable stages of memory loss.)
“By measuring three different levels in blood, free in plasma, bound to plasma components and bound to blood cells, for two of the most significant peptides, Aβ40 and Aβ42, then comparing the ratios of those levels to established diagnoses methods, we have been able to consistently show a relationship between Aβ levels and the disease,” he says.
“This means that we, and by “we” I mean Alzheimer’s’ researchers in general, are that much closer to having a reliable, minimally invasive biomarker for Alzheimer’s disease,” Professor Sarasa says. “The importance of this is that studies could recruit earlier and at much less expense. Interventional therapies can be tested in earlier stages of the disease and once an effective therapy is found, this type of test will be well suited to population screening in the public health sector.”
The results of this work are being published in the Journal of Alzheimer’s Disease 36(3) in July.
Professor Sarasa said there is already a larger multinational study underway with 255 patients and his Zaragoza-based firm, a part of the Grifols group of companies, is also looking to confirm these results with other similar groups of patients around the world.
ABOUT ARACLON BIOTECH SL
Araclon, a Grifols company, (http://www.araclon.com ) was founded in 2004 by Prof. Manuel Sarasa in Zaragoza, Spain. A company dedicated to both the early detection and treatment of Alzheimer’s disease. For more information contact Ian Sherriff [email protected], Paseo de Sagasta, 17, 2º izda, 50,008, Zaragoza, Spain. Tel +34 976 796 562 Fax +34 976 217 802
ABOUT THE JOURNAL OF ALZHEIMER’S DISEASE (JAD)
The Journal of Alzheimer’s Disease (http://www.j-alz.com) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease. The Journal is published by IOS Press (www.iospress.com).
Pérez-Grijalba V, Pesini P, Monleón I, Boada M, Tárraga L, Ruiz-Laza A, Martínez-Lage P, San-José I, Sarasa M (2013) Several Direct and Calculated Biomarkers from the Amyloid-β Pool in Blood are Associated with an Increased Likelihood of Suffering from Mild Cognitive Impairment. J Alzheimers Dis, DOI: 10.3233/JAD-121744.